Introduction {#section5-1758835919830831}
============

Cancer is still one of the most threatening diseases in the world, with high morbidity and mortality rates.^[@bibr1-1758835919830831]^ Although the therapeutic strategies (surgery, chemotherapy, radiotherapy, targeted molecular therapy, and immunotherapy) have greatly improved in recent years, effective therapeutic opportunities are still limited. Therefore, the 5-year survival rate of patients with liver, lung or lymph node metastases (advanced stage) remains disappointing.^[@bibr2-1758835919830831][@bibr3-1758835919830831][@bibr4-1758835919830831]--[@bibr5-1758835919830831]^ The addition of prognostic markers to better prognostic models could improve the outcomes of advanced or metastatic cancer patients and aid in the appropriate selection of treatment strategies as potential novel therapeutic targets.

Cancer stem cells (CSCs), a small subset of cancer cells, are responsible for the capability of self-renewal, uncontrolled proliferation and differentiation, tumor progression, and resistance to traditional therapy.^[@bibr6-1758835919830831],[@bibr7-1758835919830831]^ CSCs have been identified in many tumors, for example, lung, breast, colorectal and cervical cancer.^[@bibr8-1758835919830831][@bibr9-1758835919830831]--[@bibr10-1758835919830831]^ Nestin, namely, neural stem cell protein, a member of the class VI intermediate filament (IF) family, was first discovered as a neural stem and progenitor cells marker.^[@bibr11-1758835919830831]^ Subsequent reports suggested that Nestin is observed in nonneural tissues^[@bibr12-1758835919830831]^ and may play a role in CSC phenotypes.^[@bibr13-1758835919830831]^ Nestin is involved in tumor angiogenesis, growth and cellular processes such as cell adhesion, proliferation, migration, and invasion.^[@bibr14-1758835919830831][@bibr15-1758835919830831]--[@bibr16-1758835919830831]^ The aldehyde dehydrogenase 1 (ALDH1) gene has been mapped to chromosome 12q24.2 and is responsible for oxidation and detoxification functions.^[@bibr17-1758835919830831]^ ALDH1 is involved in cellular differentiation and proliferation and in resistance to alkylating chemotherapeutic agents.^[@bibr18-1758835919830831],[@bibr19-1758835919830831]^ ALDH1 has been identified in some tumors and acts as a promoter, inducing an epithelial-mesenchymal transition (EMT) in tumor cells.^[@bibr20-1758835919830831],[@bibr21-1758835919830831]^ ALDH1 and Nestin are expressed in some malignant tumors.^[@bibr22-1758835919830831][@bibr23-1758835919830831][@bibr24-1758835919830831]--[@bibr25-1758835919830831]^ However, there are some uncertain conclusions for ALDH1 and Nestin in advanced cancer; for example, Dong and colleagues reported that ALDH1-positive expression was not correlated with overall survival (OS) in multivariable analysis in advanced breast cancer.^[@bibr26-1758835919830831]^ However, ALDH1-positive expression was associated with worse overall survival in multivariable analysis in advanced breast cancer by Alamgeer and colleagues.^[@bibr27-1758835919830831]^ Thus, further analysis is needed to elucidate the significance of ALDH1 and Nestin in advanced cancer.

To better understand the prognostic mechanisms of ALDH1 and Nestin in advanced or metastatic cancer, we first performed a systematic meta-analysis to evaluate the benefits of ALDH1 and Nestin using multivariable survival analysis. We also conducted trial sequential analysis (TSA) to correct for the increased risk of random errors and to determine if additional studies were needed. Our study's results could assist in the selection of appropriate treatment strategies, suggest novel therapeutic targets for advanced cancer patients, and help stratify patients in future prospective clinical trials.

Materials and methods {#section6-1758835919830831}
=====================

Search strategy {#section7-1758835919830831}
---------------

This meta-analysis was performed based on the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement.^[@bibr28-1758835919830831]^ We systematically searched the *PubMed, EMBASE, EBSCO, Web of Science*, and *Cochrane Library* databases for relevant studies published prior to April 2018. The search strategy was on the basis of the following key words and search terms: 'aldehyde dehydrogenase 1 OR ALDH1 OR Nestin', 'metastatic OR advanced OR metastasized OR recurrent', 'cancer OR tumor OR carcinoma OR neoplasm', 'survival OR outcome OR prognosis' ([Table S1](https://journals.sagepub.com/doi/suppl/10.1177/1758835919830831)). The reference lists of all eligible articles were also manually reviewed to identify additional studies. Overall, three authors (SH, TH, and FH) independently assessed the publications, and discrepancies were resolved by consensus.

Eligibility criteria {#section8-1758835919830831}
--------------------

Articles that met the following inclusion criteria were selected: (1) patients were diagnosed with advanced, metastatic, or recurrent cancer; (2) prospective or retrospective clinical studies that reported sufficient information for the prognostic estimation of ALDH1 and Nestin positivity; (3) studies reported available data regarding hazard ratio (HR) and 95% confidence interval (CI) using multivariable survival analysis for prognostic indicators of OS, disease-free survival (DFS), progression-free survival (PFS), cancer-specific survival (CSS), relapse/recurrence-free survival (RFS), or metastasis-free survival (MFS); (4) if studies did not record sufficient data on HR with 95% CI, HR and 95% CI values were calculated on the basis of the described method if possible,^[@bibr29-1758835919830831],[@bibr30-1758835919830831]^ or we emailed the corresponding author to request useful information; (5) the eligible studies were limited to the English language. If the authors published multiple papers using overlapping sample data, only the study with the latest information or the largest number of patients was extracted to avoid repeated data. Studies that did not meet the above-described inclusion criteria were excluded.

Data extraction and study assessment {#section9-1758835919830831}
------------------------------------

Methodological assessment was performed based on the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) guidelines.^[@bibr31-1758835919830831]^ REMARK criteria include 20 items (introduction: 1 item, materials and methods: 10 items, results: 7 items, and discussion: 2 items), having a maximum possible score of 40. An item had the following possible values: 2 if the item was clearly described, 1 if the item was incompletely described, and 0 if the item was not applicable or not fully defined. Additionally, multivariable survival analysis adjusted factors was considered more valuable than a study using univariable survival analysis. Thus, the meta-analysis only included the prognostic data from multivariable analyses. The REMARK scores are listed in [Table S2](https://journals.sagepub.com/doi/suppl/10.1177/1758835919830831). The following data were extracted from the eligible full-text papers: the surname of the first author, publication year, number of patients, demographic data (median or mean age), study source, median or mean follow-up time, cancer type, study design, testing method, therapy regimes, sample type, cut-off value, survival rate, adjusted variables, and clinical outcomes of multivariable analysis. Any disagreements were resolved by discussion until consensus was achieved.

Statistical analysis {#section10-1758835919830831}
--------------------

Data with an HR \>1 indicated worse survival, whereas an HR \<1 indicated favorable survival. Pooled HR and 95% CI were calculated to evaluate the prognostic effect of ALDH1 and Nestin positivity using multivariable analysis for advanced cancer (OS, DFS, PFS, CSS, RFS, or MFS). Heterogeneity among the eligible studies was measured using the Cochran's Q statistic and *I*^2^ test.^[@bibr32-1758835919830831]^ According to the der Simonian--Laird method, the random-effects model was applied in the meta-analysis.^[@bibr33-1758835919830831],[@bibr34-1758835919830831]^ Both *I*^2^ \< 50% and *p* \> 0.1 were considered as signifying low-level heterogeneity. For the results (\> seven studies) with obvious heterogeneity, subgroup analyses by cancer type, study source, survival rate, age (years), detection method, and study center design, etc. were conducted to explain the possible sources of heterogeneity and the strength of the correlation among different subgroups. Sensitivity analyses were also performed to estimate the effect of each individual study on the HR value by removing one study from the analysis at a time. Publication bias was detected using Egger's and Begg's funnel plots.^[@bibr35-1758835919830831],[@bibr36-1758835919830831]^ If the meta-analysis included a small sample size, random errors may cause spurious findings.^[@bibr37-1758835919830831],[@bibr38-1758835919830831]^ TSA was performed to evaluate the required sample information.^[@bibr39-1758835919830831]^ Alpha (type I error) and beta (type II error) levels of significance of 5% and 20% were used, respectively, and the optimal a priori anticipated information size (APIS) method was set. Monitoring boundaries were constructed to decide whether a study could be terminated early. When the cumulative *Z*-curve crossed the trial sequential monitoring boundary or required information size boundary, the evidence was considered to be conclusive, and further studies were deemed unlikely to change the results; otherwise, additional clinical studies were necessary. Meta-analysis was performed with Stata software, version 12.0 (Stata Corp., College Station, TX, USA) and R software, version 3.4.2 (The R Foundation for Statistical Computing, Vienna, Austria).

Results {#section11-1758835919830831}
=======

Study characteristics {#section12-1758835919830831}
---------------------

A flow diagram of the literature search procedure is presented in [Figure 1](#fig1-1758835919830831){ref-type="fig"}. After applying the eligibility criteria, a total of 20 studies published from 2010 to 2018 were included in the meta-analysis,^[@bibr26-1758835919830831],[@bibr27-1758835919830831],[@bibr40-1758835919830831][@bibr41-1758835919830831][@bibr42-1758835919830831][@bibr43-1758835919830831][@bibr44-1758835919830831][@bibr45-1758835919830831][@bibr46-1758835919830831][@bibr47-1758835919830831][@bibr48-1758835919830831][@bibr49-1758835919830831][@bibr50-1758835919830831][@bibr51-1758835919830831][@bibr52-1758835919830831][@bibr53-1758835919830831][@bibr54-1758835919830831][@bibr55-1758835919830831]--[@bibr56-1758835919830831]^ including 2050 patients with advanced cancer. These studies were evaluated against the REMARK criteria, with a mean REMARK score of 20. A total of nine studies were conducted in Europe, two in the USA, four in China, four in Japan, and the remaining one in Korea. Among the included studies, 15 studies involving 1557 advanced cancer patients evaluated the association between ALDH1 positivity and the prognosis using multivariable analysis for CSS, OS, DFS, RFS, MFS, and PFS.^[@bibr26-1758835919830831],[@bibr27-1758835919830831],[@bibr41-1758835919830831],[@bibr43-1758835919830831],[@bibr45-1758835919830831][@bibr46-1758835919830831][@bibr47-1758835919830831][@bibr48-1758835919830831][@bibr49-1758835919830831][@bibr50-1758835919830831][@bibr51-1758835919830831]--[@bibr52-1758835919830831],[@bibr54-1758835919830831],[@bibr56-1758835919830831]^ Overall, five studies involving 493 advanced cancer patients assessed the correlation between Nestin positivity and the prognosis using multivariable analysis for OS and PFS.^[@bibr40-1758835919830831],[@bibr42-1758835919830831],[@bibr44-1758835919830831],[@bibr53-1758835919830831],[@bibr55-1758835919830831]^ The characteristics of the included studies are listed in [Table 1](#table1-1758835919830831){ref-type="table"} and [Table S3](https://journals.sagepub.com/doi/suppl/10.1177/1758835919830831).

![PRISMA diagram/flow chart.\
PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.](10.1177_1758835919830831-fig1){#fig1-1758835919830831}

###### 

Main characteristics of the eligible studies.

![](10.1177_1758835919830831-table1)

  First author                                                  Study source                                                  Age    Method        Cancer type                                         Study design                     *n*   Therapy                             Survival rate   Outcomes
  ------------------------------------------------------------- ------------------------------------------------------------- ------ ------------- --------------------------------------------------- -------------------------------- ----- ----------------------------------- --------------- ----------
  Charafe-Jauffret and colleagues^[@bibr56-1758835919830831]^   France                                                        NA     IHC           Inflammatory breast cancer                          Retrospective, multicenter       109   Surgery and adjuvant therapy        5 years         CSS, MFS
  Yoshioka and colleagues^[@bibr54-1758835919830831]^           Japan                                                         NA     IHC           Node-positive breast cancer                         Retrospective, single-center     109   Surgery and adjuvant therapy        10 years        OS, RFS
  Koukourakis and colleagues^[@bibr52-1758835919830831]^        Greece                                                        68     IHC, blind    Advanced squamous cell head-neck cancer             Retrospective, multicenter       74    Surgery and adjuvant therapy        5 years         RFS
  Dong and colleagues^[@bibr26-1758835919830831]^               China                                                         49     IHC, blind    Breast cancer with axillary lymph node metastasis   Retrospective, single-center     161   Adjuvant therapy                    5 years         OS, RFS
  Alamgeer and colleagues^[@bibr27-1758835919830831]^           Australia                                                     NA     IHC, blind    Advanced breast cancer                              Prospective trial, multicenter   119   Surgery and adjuvant chemotherapy   5 years         OS
  Qian and colleagues^[@bibr51-1758835919830831]^               Germany                                                       NA     IHC, blind    Advanced pharyngeal squamous cell carcinoma         Retrospective, multicenter       56    NA                                  \> 5 years      OS
  Qian and colleagues^[@bibr51-1758835919830831]^               Germany                                                       NA     IHC, blind    Advanced head and neck squamous cell carcinoma      Retrospective, multicenter       66    NA                                  \> 5 years      OS
  Fitzgerald and colleagues^[@bibr50-1758835919830831]^         USA                                                           NA     IHC           Metastatic colon cancer                             Retrospective, single-center     21    Surgery                             \< 5 years      OS
  Bednarz-Knoll and colleagues^[@bibr47-1758835919830831]^      Germany/ Poland                                               NA     IHC           Breast cancer with lymph node metastasis            Retrospective, multicenter       102   Surgery and adjuvant therapy        \> 5 years      DFS, MFS
  Ito and colleagues^[@bibr49-1758835919830831]^                Japan                                                         54     IHC, blind    Breast cancer with axillary lymph node metastasis   Retrospective, single-center     47    Surgery and adjuvant therapy        \> 5 years      DFS
  Xie and colleagues^[@bibr48-1758835919830831]^                China                                                         43     IHC           Advanced cervical cancer                            Retrospective, single-center     52    Surgery and adjuvant chemotherapy   5 years         OS, DFS
  Ishiguro and colleagues^[@bibr46-1758835919830831]^           Japan                                                         NA     IHC           Advanced serous ovarian carcinoma                   Retrospective, multicenter       90    Surgery and adjuvant therapy        \> 5 years      OS, PFS
  Adamczyk and colleagues^[@bibr45-1758835919830831]^           Poland                                                        55.7   IHC           Breast cancer with lymph node metastasis            Retrospective, single-center     155   Surgery and adjuvant therapy        5 years         DFS
  Miyoshi and colleagues^[@bibr43-1758835919830831]^            Japan                                                         NA     IHC           Recurrent breast cancer                             Retrospective, multicenter       318   Surgery and adjuvant therapy        10 years        OS
  Ning and colleagues^[@bibr41-1758835919830831]^               USA^[\#](#table-fn2-1758835919830831){ref-type="table-fn"}^   57.5   qRT-PCR       Metastatic colorectal cancer                        Retrospective, multicenter       78    Chemotherapy                        \< 5 years      OS, PFS
  Fusi and colleagues^[@bibr55-1758835919830831]^               Germany                                                       54     FC analysis   Metastatic melanoma                                 Retrospective, single-center     32    Chemotherapy                        1 year          OS
  Qin and colleagues^[@bibr53-1758835919830831]^                China                                                         NA     IHC           Advanced serous ovarian cancer                      Retrospective, multicenter       123   Chemotherapy                        5 years         OS
  Kuk and colleagues^[@bibr44-1758835919830831]^                Korea                                                         58     IHC           Advanced melanoma                                   Retrospective, single-center     33    Surgery and adjuvant therapy        5 years         PFS
  Zhang and colleagues^[@bibr42-1758835919830831]^              China                                                         NA     IHC           Advanced hepatocellular carcinoma                   Retrospective, single-center     220   Surgery and chemotherapy            \< 3 years      OS, PFS
  Onisim and colleagues^[@bibr40-1758835919830831]^             Romania                                                       56     IHC           Advanced serous ovarian carcinoma                   Retrospective, single-center     85    Surgery and chemotherapy            5 years         OS, PFS

Note: the studies from Charafe-Jauffret 2010 to Ning 2018 were of ALDH1 and the studies from Fusi 2011 to Onisim 2016 were of Nestin.

stands for the mixed population.

CSS, cancer-specific survival; DFS, disease-free survival; FC, flow cytometry; IHC, immunohistochemistry; MFS, metastasis-free survival; *N*, number of cases; NA, not applicable; OS, overall survival; PFS, progression-free survival; qRT-PCR, real-time quantitative PCR; RFS, relapse/recurrence-free survival.

Association between ALDH1 positivity and the prognosis {#section13-1758835919830831}
------------------------------------------------------

CSS was only available in one study with 77 cases that showed that ALDH1 positivity was correlated with a poor CSS (5-year CSS: HR = 2.7, 95% CI = 1.48--4.93; [Figure 2](#fig2-1758835919830831){ref-type="fig"}). There was no statistically significant correlation with DFS (*n* = four studies with 333 cases, HR = 0.95, 95% CI = 0.38--2.36, *p* = 0.907), RFS (*n* = three studies with 344 cases, HR = 0.90, 95% CI = 0.41--1.99, *p* = 0.797), MFS (*n* = two studies with 112 cases, HR = 1.04, 95% CI = 0.16--6.70, *p* = 0.97), or PFS (*n* = two studies with 168 cases, HR = 1.32, 95% CI = 0.65--2.68, *p* = 0.445; [Figure 2](#fig2-1758835919830831){ref-type="fig"}). Data from 10 studies indicated that ALDH1 positivity was significantly correlated with a negative effect on OS with an HR of 2.28 (95% CI: 1.59--3.27, *p* \< 0.001, *n* = 1070 cases; [Figure 3](#fig3-1758835919830831){ref-type="fig"}). Additionally, three studies did not report information about the use of adjuvant therapy, so we recalculated the OS results of the remaining seven studies using adjuvant therapy and found that ALDH1 positivity was still correlated with a worse OS (HR = 1.84, 95% CI = 1.29--2.62, *p* = 0.001; [Figure 3](#fig3-1758835919830831){ref-type="fig"}).

![Forest plot of the association between ALDH1 positivity and DFS, RFS, MFS, PFS, and CSS.\
ALDH1, aldehyde dehydrogenase 1; CSS, cancer-specific survival; DFS, disease-free survival; MFS, metastasis-free survival; PFS, progression-free survival; RFS, relapse/recurrence-free survival.](10.1177_1758835919830831-fig2){#fig2-1758835919830831}

![Forest plot of the association between ALDH1 positivity and OS.\
ALDH1, aldehyde dehydrogenase 1; OS, overall survival.](10.1177_1758835919830831-fig3){#fig3-1758835919830831}

Subgroup and sensitivity analyses of ALDH1 positivity in OS {#section14-1758835919830831}
-----------------------------------------------------------

The results of subgroup analyses by the possible sources of heterogeneity for the OS results are listed in [Table 2](#table2-1758835919830831){ref-type="table"}. Most subgroups were not significantly changed by the study factors for heterogeneity. The testing method and treatment regimens could reduce the level of statistical heterogeneity (testing method: blind, *I*^2^ = 72.2% and *p* = 0.013; NA, *I*^2^ = 30.3% and *p* = 0.208; treatment regimens: surgery with adjuvant therapy, *I*^2^ = 32.9% and *p* = 0.202; others, *I*^2^ = 68.0% and *p* = 0.014). In addition, the strength of the association among different subgroups was evaluated and there was a significant association for patients with head and neck carcinoma (*n* = 122 case, HR = 3.99, *p* \< 0.001), cervical cancer (*n* = 52 case, HR = 3.51, *p* = 0.034), and ovarian carcinoma (*n* = 90 case, HR = 2.51, *p* = 0.003). Data from four studies with 707 cases showed a trend towards poor OS in breast cancer patients (HR = 1.67, 95% CI = 0.97--2.87, *p* = 0.062), but no association was found for colorectal cancer (two studies with 99 cases: HR = 2.30, 95% CI = 0.79--6.70, *p* = 0.129). Subgroup analysis by study source showed that ALDH1 positivity was linked to a shorter OS in Japanese (three studies with 517 cases: HR = 1.94, 95% CI = 1.28--2.92, *p* = 0.002) and Europeans (four studies with 262 cases: HR = 4.15, 95% CI = 2.46--7.03, *p* \< 0.001), but not in Chinese (two studies with 213 cases: HR = 1.61, 95% CI = 0.40--6.53, *p* = 0.506). Stratified analysis based on survival rate indicated that ALDH1 positivity was correlated with a poor prognosis in terms of ⩾5-year OS (eight studies with 971 cases: HR = 2.33, 95% CI = 1.54--3.53, *p* \< 0.001), and further pooled HR from two studies with 427 cases resulted in a decreased OS at 10 years (HR = 1.76, 95% CI = 1.03--3.00, *p* = 0.038),^[@bibr43-1758835919830831],[@bibr54-1758835919830831]^ but no association at \<5-year OS (two studies with 99 cases: HR = 2.30, 95% CI = 0.79--6.70, *p* = 0.129). Significant associations were noted between other subgroup analyses (testing method, study center design, and treatment regimens).

###### 

Summary of ALDH1 by subgroup analyses in OS.

![](10.1177_1758835919830831-table2)

  Factors               Subgroups                      Studies   HR with 95% CI       *p* value   Heterogeneity (*I*^2^; *p*)   Cases   TSA
  --------------------- ------------------------------ --------- -------------------- ----------- ----------------------------- ------- ---------
  Tumor type            Breast cancer                  4         1.67 (0.97--2.87)    0.062       53.1%; 0.094                  707     More
                        Colorectal cancer              2         2.30 (0.79--6.70)    0.129       62.0%; 0.105                  99      More
                        Head and neck carcinoma        2         3.99 (2.08--7.64)    \< 0.001    0.0%; 0.325                   122     More
                        Cervical cancer                1         3.51 (1.11--11.25)   0.034       NA                            52      NA
                        Ovarian carcinoma              1         2.51 (1.36--4.56)    0.003       NA                            90      NA
  Study source          Japanese                       3         1.94 (1.28--2.92)    0.002       39.7%; 0.190                  517     More
                        Chinese                        2         1.61 (0.40--6.53)    0.506       75.0%; 0.046                  213     More
                        European                       4         4.15 (2.46--7.03)    \< 0.001    0.0%; 0.798                   262     More
                        Mixed population               1         1.45 (0.72--2.92)    0.298       NA                            78      NA
  Survival rate         ⩾5 years                       8         2.33 (1.54--3.53)    \< 0.001    55.9%; 0.026                  971     No need
                        \<5 years                      2         2.30 (0.79--6.70)    0.129       62.0%; 0.105                  99      More
  Age (years)           ⩽60                            3         1.47 (0.73--2.98)    0.286       50.3%; 0.134                  291     More
                        NA                             7         2.71 (1.80--4.09)    \< 0.001    48.8%; 0.068                  779     No need
  Testing method        Blind                          4         2.74 (1.07--7.01)    0.036       72.2%; 0.013                  402     More
                        NA                             6         2.05 (1.46--2.88)    \< 0.001    30.3%; 0.208                  668     More
  Study center design   Multicenter                    6         2.34 (1.51--3.62)    \< 0.001    53.5%; 0.056                  727     More
                        Single-center                  4         2.24 (1.05--4.77)    0.036       61.2%; 0.052                  343     More
  Treatment regimens    Surgery and adjuvant therapy   5         2.18 (1.48--3.23)    \< 0.001    32.9%; 0.202                  688     More
  　                    Others                         5         2.35 (1.17--4.72)    0.017       68.0%; 0.014                  382     More

ALDH1, aldehyde dehydrogenase 1; CI, confidence interval; HR, hazard ratio; NA, not applicable; OS, overall survival; TSA, trial sequential analysis.

Sensitivity analysis was conducted based on the omission of one study at a time, and when the studies of Dong and colleagues^[@bibr26-1758835919830831]^ or Miyoshi and colleagues^[@bibr43-1758835919830831]^ were removed, heterogeneity was lacking (*I*^2^ = 0.0% and *p* = 0.442), but the HR was not significantly changed (HR = 2.75, 95% CI = 2.03--3.73, *p* \< 0.001).

Association between Nestin positivity and the prognosis {#section15-1758835919830831}
-------------------------------------------------------

Data from four studies with 460 cases demonstrated that Nestin-positive expression was associated with significantly poorer OS (HR = 2.39, 95% CI = 1.86--3.05, *p* \< 0.001, *I*^2^ = 0.0%; [Figure 4](#fig4-1758835919830831){ref-type="fig"}) and Nestin-positive expression was also significantly linked to a worse PFS (three studies with 338 cases: HR = 2.08, 95% CI = 1.58--2.73, *p* \< 0.001, *I*^2^ = 0.0%; [Figure 4](#fig4-1758835919830831){ref-type="fig"}).

![Forest plot for the association between Nestin positivity and OS and PFS.\
OS, overall survival; PFS, progression-free survival.](10.1177_1758835919830831-fig4){#fig4-1758835919830831}

Publication bias {#section16-1758835919830831}
----------------

The funnel plots showed that a slight publication bias existed regarding OS and ALDH1 (Egger's test: *p* = 0.037 \< 0.05), but no publication bias existed regarding OS (Begg's test: *p* = 0.074; [Figure S1](https://journals.sagepub.com/doi/suppl/10.1177/1758835919830831)).

TSA {#section17-1758835919830831}
---

The relative risk reduction of 20%, type I error α (5%), and type II error β (20%; power of 80%) were used. The TSA showed that the cumulative *Z*-curve crossed the trial sequential monitoring boundary regarding OS of ALDH1 and Nestin positivity ([Figures S2 and 3](https://journals.sagepub.com/doi/suppl/10.1177/1758835919830831)) and the subgroup of ALDH1 at ⩾5-year OS ([Table 2](#table2-1758835919830831){ref-type="table"}), suggesting that further studies are unlikely to change these results. However, for most subgroups of ALDH1 ([Table 2](#table2-1758835919830831){ref-type="table"}), the results of Nestin positivity for PFS ([Figure S4](https://journals.sagepub.com/doi/suppl/10.1177/1758835919830831)), and the results of ALDH1 for DFS, RFS, MFS, or PFS ([Table S4](https://journals.sagepub.com/doi/suppl/10.1177/1758835919830831)), showed that the cumulative *Z*-curve did not cross the trial sequential monitoring boundary, suggesting that additional studies are needed. For the above results from the sensitivity analysis, further TSA still showed that the cumulative *Z*-curve was more than the trial sequential monitoring boundary ([Figure S5](https://journals.sagepub.com/doi/suppl/10.1177/1758835919830831)), further suggesting that additional studies are not needed.

Discussion {#section18-1758835919830831}
==========

Epithelial tumors are generally heterogeneous cell populations with highly variable abilities of survival, growth, and metastasis.^[@bibr57-1758835919830831]^ Emerging evidence suggests that the top of the cellular hierarchy is a CSC population that can self-renew, proliferate and differentiate into progeny cells, thus causing the cellular and functional heterogeneity within epithelial tumors.^[@bibr58-1758835919830831],[@bibr59-1758835919830831]^ CSCs have been reported in many tumors, such as breast, lung, melanoma, and colorectal cancers.^[@bibr60-1758835919830831]^ Wu and colleagues reported that Nestin-positive expression was correlated with worse survival in glioma.^[@bibr24-1758835919830831]^ Shan and colleagues found that weak Nestin expression was associated with favorable survival in ampullary adenocarcinoma.^[@bibr61-1758835919830831]^ Some studies reported that ALDH1-positive expression was linked to decreased survival outcomes in lung, bladder, and breast cancers,^[@bibr62-1758835919830831][@bibr63-1758835919830831]--[@bibr64-1758835919830831]^ while other studies reported that loss of ALDH1 was correlated with shortened survival in pancreatic and lung cancers.^[@bibr65-1758835919830831],[@bibr66-1758835919830831]^ However, the prognostic effect of ALDH1 and Nestin in patients with advanced or metastatic cancer remains unclear and the present meta-analysis was conducted to better clarify the characteristics of CSCs expressing ALDH1 and Nestin. This information added to the current prognostic models could guide the development of new therapeutic strategies for advanced or metastatic cancer by identifying them as effective therapeutic and prognostic targets in clinical practice.

Conventional chemotherapy and radiation therapy are two common useful strategies to eliminate cancer cells and shrink tumors. However, chemotherapy/radiotherapy resistance and disease recurrence are major challenges for the long-term survival of cancer patients.^[@bibr67-1758835919830831][@bibr68-1758835919830831]--[@bibr69-1758835919830831]^ Thus, understanding the mechanisms of chemoresistance and radioresistance are important for improving chemotherapy and radiation therapy. The reasons for cancer drug resistance are very complex and affected by many factors, which also affect therapy efficacy.^[@bibr70-1758835919830831][@bibr71-1758835919830831]--[@bibr72-1758835919830831]^ Importantly, recent studies have suggested that CSCs are resistant to traditional chemotherapy and radiotherapy.^[@bibr73-1758835919830831],[@bibr74-1758835919830831]^ Some mechanisms, such as important signaling pathways (e.g. PI3K/Akt/mammalian target of rapamycin, vascular endothelial growth factor, Notch, and Wnt/β-catenin pathways) are closely correlated with CSCs.^[@bibr75-1758835919830831]^ Therefore, targeting CSCs may be a promising approach to curing cancer patients.^[@bibr76-1758835919830831]^ Based on the recommended adjustment of survival analysis for known prognostic factors, a comprehensive analysis of published studies (ALDH1: 15 studies with 1557 cases and Nestin: 5 studies with 493 patients with advanced cancer who received adjuvant chemotherapy/radiotherapy) was performed. We found that ALDH1 positivity was significantly associated with a shorter OS (HR = 2.28, *p* \< 0.001) but was not linked to DFS, RFS, MFS, or PFS. Additionally, evidence from some previously published studies is consistent with our analyses, where ALDH1 positivity was found to be correlated with worse OS in advanced cancers.^[@bibr27-1758835919830831],[@bibr46-1758835919830831],[@bibr48-1758835919830831],[@bibr50-1758835919830831],[@bibr51-1758835919830831],[@bibr54-1758835919830831]^ A possible explanation for the results for the other outcomes might be different definitions of the various non-OS outcome measures.^[@bibr77-1758835919830831],[@bibr78-1758835919830831]^ OS is almost always defined as the time from study enrollment to the date of death from any cause or the last follow up. OS is the most common standard endpoint because it is easy to measure and interpret and it is completely objective and unbiased.^[@bibr79-1758835919830831]^ We also found that the sample sizes in our analyses regarding the other outcome measurements (DFS, RFS, MFS, and PFS) were small (\<350 patients per outcome measurement), which was confirmed by TSA. Further analysis of only the seven studies with 927 advanced cancer patients treated with adjuvant therapy also showed a significant association between ALDH1 positivity and poor OS (HR = 1.84, *p* = 0.001). Nestin-positive expression was also correlated with a significantly shorter OS (HR = 2.39, *p* \< 0.001) and PFS (HR = 2.08, *p* \< 0.001). These findings were verified by TSA and the results suggested that additional clinical studies are not needed to confirm these conclusions regarding OS of ALDH1 and Nestin. Our analyses suggest that ALDH1 and Nestin may be effective therapeutic targets to eliminate the subpopulation of CSCs and this may improve the treatment outcome of patients with advanced cancer.

Stratified analysis by cancer type suggested that ALDH1 positivity may be correlated with inferior OS in breast (HR = 1.67, *p* = 0.062), head and neck (HR = 3.99, *p* \< 0.001), cervical (HR = 3.51, *p* = 0.034), and ovarian carcinomas (HR = 2.51, *p* = 0.003) but was not associated with OS in colorectal cancer (*p* = 0.129), suggesting that ALDH1 may play different roles in different cancer types and could become a potential target for the treatment of advanced breast, head and neck, cervical, and ovarian cancers. Moreover, evidence from some of the previously published studies on these specific tumor types is consistent with ours, such as colorectal cancer,^[@bibr41-1758835919830831]^ breast cancer,^[@bibr27-1758835919830831],[@bibr54-1758835919830831]^ and head and neck carcinoma.^[@bibr51-1758835919830831]^ Stratified analysis by study source indicated that ALDH1 positivity was associated with a shorter OS for Japanese (HR = 1.94, *p* = 0.002) and Europeans (HR = 4.15, *p* \< 0.001), but there was no association for Chinese (*p* = 0.506), which suggested that ALDH1 might only play a role in Japanese and European patients with advanced cancer and this may have potential implications to help stratify patients for treatment and prognostication. It is also possible that early detection, treatment schedules, and cancer-related lifestyles might to some extent differ in China compared with the rest of the world,^[@bibr80-1758835919830831],[@bibr81-1758835919830831]^ which might have contributed to the lack of an association of the ALDH1 marker with the OS of Chinese patients. Stratified analysis by survival rate demonstrated that ALDH1 positivity was linked to an unfavorable OS at ⩾5 years (HR = 2.33, *p* \< 0.001), and further analysis showed a reduced long-term OS rate at 10 years (HR = 1.76, *p* = 0.038). However, the eligible studies did not report long-term follow-up results, such as 10 years in terms of Nestin. According to the present analyses, ALDH1 might be a more important and meaningful marker than Nestin in advanced cancer. The above results of the subgroups were further confirmed by TSA, which suggested that more clinical studies were necessary to confirm these conclusions except for the subgroup of ⩾5-year OS.

Some limitations should be acknowledged. First, although we systematically searched the relevant databases as completely as possible, a slight publication bias was noted for the OS of ALDH1 data. Potential explanations for this are: (1) only final eligible studies published in English were selected. Studies of other types, such as unpublished papers or conference abstracts, were excluded because of incomplete information; (2) papers with positive results are more easily published than papers with negative results found in survival analyses, which are therefore lacking. Second, although the results were confirmed by TSA, and TSA suggested that only the results for OS were firm, most of these studies were retrospective in design. Third, the testing method and treatment regimens may impact the current findings of the subgroup analyses in this meta-analysis. Cancer is a heterogeneous disease and different cancer types may impact overall effect estimates; however, we did not find this factor to be a potential source of heterogeneity, possibly because the number of the eligible cancer types was relatively small. Fourth, we found that most eligible studies did not report that the assessors of the Nestin and ALDH1 tests were blinded to clinical findings. Finally, the REMARK guidelines only evaluate the reporting aspect of each study and they are not a tool for study quality assessment, because reporting quality and study quality are not necessarily interchangeable. For example, a prospective study design is more valuable and more easily achieved in a clinic in the future than any retrospective study design.

To conclude, our meta-analysis and TSA indicated that ALDH1 and Nestin were associated with shorter OS, and these two results were reliable. Nestin positivity may be correlated with a worse PFS, but ALDH1 positivity was not linked to DFS, RFS, MFS, or PFS. Subgroup analysis by cancer type showed that ALDH1 positivity may be correlated with poor OS in breast, head and neck, cervical, and ovarian cancers, but there was no association in colorectal cancer. Subgroup analysis by study source showed that ALDH1 positivity was linked to a worse OS for Japanese and European patients, but there was no correlation for Chinese patients. Subgroup analysis by survival rate demonstrated that ALDH1 positivity was associated with an unfavorable OS at 10 years. ALDH1 may be valuable as a potential effective therapeutic target for the improvement of treatment of advanced cancer in clinical practice. Additional high-quality, prospective, randomized clinical trials are needed to provide more conclusive evidence in different types of advanced cancer.
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